Wilmington, DE -- (SBWIRE) -- 12/17/2013 -- -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Amgen Inc. (NASDAQ:AMGN) and Ctrip.com International Ltd. (NASDAQ:CTRP).
Amgen Inc. (NASDAQ:AMGN) a biotechnology medicines company that engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada closed down in its previous session (-0.04%) on 2,073,963 shares traded after Amgen Announced 2014 First Quarter Dividend. Amgen Inc. (NASDAQ:AMGN) is currently down (-6.37%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Amgen Inc. (NASDAQ:AMGN)
Ctrip.com International Ltd. (NASDAQ:CTRP) a company that together with its subsidiaries, provides travel service for hotel accommodations, airline tickets, packaged tours, and corporate travel management in the Peoples Republic of China closed up in its previous session (+0.40%) on 2,302,351 shares traded. Ctrip.com International Ltd. (NASDAQ:CTRP) is currently up (+155.8%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Ctrip.com International Ltd. (NASDAQ:CTRP)
Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Equityprofilereport.com
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.
Equity Profile Report